Clinical trials: Motor Neuron Disease (MND)
Amyotrophic Lateral Sclerosis
Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001
Provides up to six months treatment with CuATSM for subjects who have successfully completed study CMD-2019-001
- Trial name
- NCT04313166
- Testing
- Cu(II)ATSM
- Where
- Australia
- Volunteers
- 55 people
- Sponsor
- Collaborative Medicinal Development Pty Limited
Amyotrophic Lateral Sclerosis, ALS
Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis
The purpose of this study is to evaluate the safety and efficacy of autologous bone marrow-derived stem cells("HYNR-CS inj"), through intrathecal delivery for the treatment in patients with ALS. This study consists of 2 steps.
- Trial name
- NCT01363401
- Testing
- HYNR-CS inj, Control group
- Where
- South Korea
- Volunteers
- 72 people
- Sponsor
- Corestemchemon, Inc.
Cystic Fibrosis, Motor Neuron Disease
MN4000 for Treatment of CF and MND Patients in the Home Setting
The study was a non-randomized open label pilot study. It was an observational design conducted at one (1) site in the US. All enrolled subjects received treatment with the MN4000.
- Conditions
- Cystic Fibrosis, Motor Neuron Disease, Airway Clearance Impairment
- Trial name
- NCT03797677
- Testing
- MN 4000
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Hill-Rom
ALS (Amyotrophic Lateral Sclerosis), ALS
Kamlanoflast In Amyotrophic Lateral Sclerosis
This is a study of Kamlanoflast in patients with ALS. Kamlanoflast is orally administered over 24 weeks. Its effects on inflammatory and functional parameters will be studied.
- Conditions
- ALS (Amyotrophic Lateral Sclerosis), ALS, Neuro-Degenerative Disease, Neuro-Degenerative Diseases
- Trial name
- NCT07396818
- Testing
- Kamlanoflast
- Volunteers
- 40 people
- Sponsor
- Inflammasome Therapeutics
Amyotrophic Lateral Sclerosis
IC14 for Rapidly Progressive Amyotrophic Lateral Sclerosis (ALS)
Patients with rapidly progressive ALS will be assigned to IC14 intravenously on Day 1-4. This 4-day course will be repeated on Days 8-11.
- Trial name
- NCT03474263
- Testing
- Biologic: IC14 (monoclonal antibody against human CD14)
- Where
- Australia
- Sponsor
- Implicit Bioscience
Amyotrophic Lateral Sclerosis
CuATSM Compared With Placebo for Treatment of ALS/MND
Multicenter, randomized, double-blind, placebo controlled study to assess the tolerabilty and efficacy of CuATSM in patients with ALS/MND.
- Trial name
- NCT04082832
- Testing
- Cu(II)ATSM
- Where
- Australia
- Volunteers
- 80 people
- Sponsor
- Collaborative Medicinal Development Pty Limited
Motor Neuron Disease
A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.
The COMMEND Study will assess the safety and effectiveness of FLX-787 in men and women with Motor Neuron Disease [including Amyotrophic Lateral Sclerosis (ALS), Primary Lateral Sclerosis (PLS) or Progressive Muscular Atrophy…
- Trial name
- NCT03196375
- Testing
- FLX-787-ODT (orally disintegrating tablet)
- Where
- 35 sites in United States
- Volunteers
- 54 people
- Sponsor
- Flex Pharma, Inc.
Neurologic Disorder, Neurologic Diseases
Functional Outcomes and Control Using Synchron BCI - Australia
Functional Outcomes and Control Using Synchron BCI - Australia (FOCUS-AUS)
- Conditions
- Neurologic Disorder, Neurologic Diseases, MND (Motor Neurone DIsease), Motor Neuron Disease
- Trial name
- FOCUS-AUS (NCT07533903)
- Testing
- Stentrode
- Where
- Australia
- Volunteers
- 10 people
- Sponsor
- Synchron, Inc.
Amyotrophic Lateral Sclerosis
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT03127267
- Testing
- Masitinib (6.0), Riluzole, Masitinib (4.5)
- Where
- 56 sites in United States, Belgium and 15 more
- Volunteers
- 495 people
- Sponsor
- AB Science
Neurologic Disorder, ALS
Functional Outcomes and Control Using Synchron BCI - Canada
Functional Outcomes and Control Using Synchron BCI - Canada (FOCUS-CAN)
- Conditions
- Neurologic Disorder, ALS, Motor Neuron Disease
- Trial name
- FOCUS-CAN (NCT07446114)
- Testing
- Stentrode
- Where
- 2 sites in Canada
- Volunteers
- 10 people
- Sponsor
- Synchron, Inc.
Amyotrophic Lateral Sclerosis (ALS)
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
This is a multicenter, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early-stage ALS (within 2 years of ALS symptoms onset).
- Trial name
- ASTRALS (NCT06643481)
- Testing
- VHB937
- Where
- 74 sites in United States, Australia and 15 more
- Volunteers
- 251 people
- Sponsor
- Novartis Pharmaceuticals
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND
Multicenter, open-label , single and multiple dose-escalation and pharmacokinetic study
- Trial name
- NCT02870634
- Testing
- Cu(II)ATSM
- Where
- 2 sites in Australia
- Volunteers
- 50 people
- Sponsor
- Collaborative Medicinal Development Pty Limited